Hepatology

New study shows age predicts six-week mortality in cirrhotic patients after acute gastrointestinal bleeding, with potential to improve risk stratification.

New research shows that bacteria normally found in the mouth can travel to the gut and promote liver scarring by damaging the gut barrier.

A global report shows uneven progress toward WHO hepatitis elimination goals, highlighting persistent policy and implementation gaps in testing and treatment.

A new study shows that the triglyceride-glucose-waist-to-height ratio may help predict NAFLD risk in older adults, offering a simple screening tool.

New research suggests a blood-based test could improve early detection of liver cancer in high-risk patients.

New data show that alcohol-related liver disease continues to drive liver mortality, even where overall alcohol consumption has declined.

New research suggests that abnormal sleep duration may be associated with increased risk of chronic liver disease, particularly in people with metabolic risk factors.

A new global report shows uneven progress towards viral hepatitis elimination, with major gaps in diagnosis and treatment contributing to ongoing liver-related deaths.

New research has identified a liver-specific receptor, GPR110, as a key driver of sex-related differences in the progression of metabolic dysfunction-associated steatohepatitis.

New research calls for routine risk stratification of MASLD in people with obesity to detect and manage liver disease earlier.

A major UK trial launched to screen up to 42,000 adults in primary care for early liver disease using non-invasive testing.

Molecular profiling and matched targeted treatment significantly improved survival in advanced cholangiocarcinoma in a large Italian real-world study.

Patients who survive colorectal cancer face a sustained and increased risk of death from chronic liver disease and cirrhosis long after surgery, according to a large population-based analysis from the United States.

A Japanese cohort study has identified distinct liver enzyme trajectories in early adulthood that are strongly associated with the risk of developing type 2 diabetes.

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically meaningful responses that improve patient outcomes, even without full antigen clearance.

By reconstructing a fetal liver–specific niche, FLOs enable simultaneous development of hepatic and hematopoietic lineages, revealing cross-talk essential for understanding human liver development and immune injury.

AI-enhanced ECG screening uncovers silent liver cirrhosis, enabling earlier diagnosis and intervention in routine primary care.

A long-term study shows that recurrence beyond the Milan criteria, rather than recurrence itself, drives poorer survival after curative hepatocellular carcinoma resection.

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure and introduces a nomogram to predict 8-year HCC risk.

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

A phase 2 trial finds tinengotinib demonstrates anti-tumour activity in previously treated advanced cholangiocarcinoma with FGFR alterations.

A new multinational study reports that rifaximin use in cirrhosis and hepatic encephalopathy is linked to significantly higher risks of antimicrobial resistance and severe infections.

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory.

New research confirms the GOLDEN model reliably predicts HBsAg loss in interferon-treated chronic hepatitis B patients, supporting more personalized treatment strategies.

Bioinformatics work identifies FAM72A–D as powerful prognostic markers in liver cancer and unveils a compact FAM72 risk score that outperforms existing gene models.

Silencing S100A11 protects against steatosis, inflammation and fibrosis in murine MASH, uncovering HK2 as a key metabolic driver and potential therapeutic target.

High-dose aluminum adjuvant Imject Alum induces immune-mediated liver inflammation and fibrosis in mice, offering a new preclinical model that mirrors human cirrhosis biology.

A new review finds statins remain safe and effective in MASLD, while evidence for PCSK9 inhibitors is promising but still limited.

Chinese surgeons have performed the first living pig-to-human liver xenotransplant, showing that a gene-edited porcine liver can support human function for weeks.

A major review suggests coffee’s bioactive compounds may help lower liver cancer risk, though benefits vary by intake, preparation method and individual lifestyle factors.

A new study suggests that the cholesterol-regulating protein PCSK9 may serve as a sensitive early biomarker for autoimmune liver diseases, helping identify patients even when routine liver tests appear normal.

New research shows that blood types A and B are linked to a higher risk of autoimmune liver disease.

Many people with primary biliary cholangitis are not receiving recommended alkaline phosphatase monitoring, and adherence is markedly higher among those under specialist care.

Semaglutide 2.4 mg/week reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits.

New European research reveals that remission in autoimmune hepatitis does not guarantee recovery, with many patients reporting fatigue and poor quality of life.

Mazdutide, a dual GLP-1 and glucagon receptor agonist, significantly reduced liver fat and improved metabolic markers in people with MASLD and obesity.

New research found early Alzheimer’s markers in rats with liver dysfunction, suggesting liver health may play a key role in dementia risk.

Recent research has examined the dual benefits of dietary patterns that improve MASLD outcomes while reducing environmental impact.

Elevated serum tyrosine predicts HCC and mortality in chronic liver disease, helping identify high-risk patients for closer monitoring.

Interestingly, the timing of vaccination, often initiated within 12 months post-transplant, did not significantly influence antibody development.

While the control group demonstrated no notable change, the intervention group showed a clear improvement in knowledge immediately after completing the VR module.

By targeting the gut-liver axis, administration of L. reuteri or ILA could become a novel therapeutic approach to prevent TACE-LI.

Discover a study showing how PEth levels identify alcohol use and predict adverse outcomes in MASLD, MetALD, and ALD patients.

The DRIVE-C study in Haiphong, Vietnam, evaluated a community-based strategy to screen PWID for HCV and provide access to direct-acting antivirals.

A randomised controlled trial examined the effectiveness of facilitated telemedicine for hepatitis C virus treatments.

A 12-month randomised controlled trial investigated curcumin supplementation in Type 2 diabetes treatment, specifically its effects on liver steatosis.

The study examined transcriptome data from patients with HBV-induced acute liver failure and healthy controls, identifying key genes and pathways linked to disease progression.

Interestingly, liver transplant recipients did not experience excess mortality, likely due to restored liver function post-transplant.

Discover a study highlighting how small-incision large-expansion improves PAD treatment outcomes, offering safer, faster stone removal and preserved sphincter function.

This investigation examined 72 patients with hepatitis virus infection or alcohol-related liver disease across various stages, providing a detailed picture of immune changes in cirrhosis.

For individuals with MASLD and Type 2 diabetes, these findings suggest that tirzepatide and semaglutide could play a significant role in reducing liver-related complications

Crucially, these trends were observed for overall survival as well and were successfully reproduced in the separate validation set.

Traditionally, most European and Spanish guidelines recommend viral hepatitis screening only in individuals with recognised risk factors or elevated liver enzyme levels.

Discover a study showing how HCV eradication with antivirals during immunotherapy improves survival, liver function, and treatment outcomes in advanced hepatocellular carcinoma.

Recent research has investigated whether low-molecular-weight fucoidan, a compound derived from brown seaweed, could enhance the efficacy of TACE.

A new randomised controlled trial has investigated the impact of dietary fibre supplementation on patients with T2DM and MASLD.

Discover a study showing how resistance training can improve inflammation, oxidative stress, and physical performance in patients with liver cirrhosis.

A recent study has identified the multifunctional protein G3BP1 as a key regulator of lipid metabolism in the liver.

The results demonstrated a high probability, 97.3%, that shorter durations of antibiotic prophylaxis, including no treatment, were noninferior to longer durations for all-cause mortality.

Discover a study showing that post-treatment AFP levels help predict hepatocellular carcinoma risk in chronic hepatitis C patients after antiviral therapy.

Potential mechanisms behind BSV’s protective effect may mirror those described for tenofovir-based therapies, such as modulation of inflammatory and oncogenic pathways.

Emerging evidence points to the role of CD4+ T cell subsets in fuelling MAFLD-related inflammation and fibrosis.

Learn how new research links major air pollutants with increased NAFLD risk, urging broader public health focus.

Understand how paternal hepatitis B has no significant effect on ART pregnancy or live birth outcomes.

Combined liver transplant and sleeve gastrectomy yield lasting weight loss and fewer metabolic complications in patients with obesity.

The team concluded that CLD remains a major health burden in Thailand, highlighting the need for strong prevention strategies, early diagnosis, and equitable access to effective therapies.

Discover a study exploring how verbal instructions and symptom expectations influence fatigue and motivation in people living with primary biliary cholangitis.

The findings suggest that a multi-marker, multi-pathway approach can account for the heterogeneous ways HCC emerges.

This nationwide South Korean cohort study examined over six million young adults aged 20–39 years to assess new-onset AF according to contemporary SLD subtypes.

A case series has reported the first successful use of combined liver and haploidentical stem cell transplantation to cure patients with severe sickle cell disease (SCD) complicated by advanced liver failure.

Emerging evidence also implicates air pollution in metabolic disorders common in later life, including dyslipidaemia, weight gain and impaired glucose homeostasis.

In this randomised prospective study, 72 living liver donors scheduled for right hepatectomy were enrolled and divided into two groups.

Silymarin, vitamin E, and phospholipids combination therapy effectively reduces liver steatosis, fibrosis, and metabolic risk in MASLD.

Exc: Adults received three consecutive FMTs, either allogeneic (from healthy donors) or autologous (their own stool), with liver fat measured by MRI-derived proton density fat fraction.

Discover a study assessing whether a five-minute rapid antibody test can speed up hepatitis C diagnosis. Read on.

New findings suggest that non-targeted screening for hepatitis C virus may be more effective than targeted screening for identifying new HCV infections in the emergency department.

Ascorbic acid (AA) supplementation could potentially reduce post-reperfusion syndrome (PRS) during liver transplantation

Vitamin D boosts UDCA treatment success inpatients with PBC, improving liver function and reducing hepatic fibrosis progression.

Learn how cholecystectomy may raise the risk of MASLD, particularly in patients with obesity, diabetes, or high blood pressure. Read the full study findings.

Discover a study evaluating how intrathecal morphine improves early postoperative pain relief and reduces morphine use after open liver surgery.

If validated in larger, diverse populations, the VAS-MASH-US score could represent a major advancement in hepatology.

The study explored the anti-inflammatory and analgesic effects of low-dose ketamine and Dex, both commonly used anaesthetic agents with known immune-modulating properties.

This study focused on eGDR, a widely accessible proxy for insulin sensitivity derived from waist circumference, hypertension status, and HbA1c levels.

Key findings showed a clear, stepwise increase in risk of complications, including heart failure, stroke, and cardiac arrest, as liver fibrosis scores rose.

In patients with advanced chronic liver disease, several factors such as diet, changes in gut bacteria, and disruption of the gut–vascular barrier can lead to altered levels of TMA and TMAO.

Discover how SGLT-2 inhibitors are linked with reduced risk of serious liver events in cirrhosis patients.

The study highlights stark contrasts in ACLF triggers across regions: HBV predominates in Eastern countries such as China, while alcohol is the main culprit in the West.

Discover a study revealing how subclinical liver fibrosis, measured by FIB-4, predicts increased mortality risk in coronary artery disease patients.

While other machine learning models like MoRAL-AI and TRAIN-AI have also shown promise, TRIUMPH distinguishes itself through its robust generalisability.

While the primary outcome, a ≥10% reduction in α-SMA, was reached in 29% of ReFerm® recipients versus 14% in the control group, the difference was not statistically significant.

Using superconducting quantum interference device magnetometry, researchers examined the magnetic properties of post-mortem brainstem tissue from four individuals.

Large UK studies show no increased liver cancer risk with oral contraceptives, though longer use may slightly raise risk.

In this study, MASLD was identified in 50% of the T2DM cohort using non-invasive methods, slightly lower than some global estimates.

Discover a study exploring how gut microbiome imbalances contribute to MASLD progression and offer new diagnostic and therapeutic possibilities.

Metabolic and genetic disorders emerged as the most frequent aetiological group, reflecting broader diagnostic capabilities compared to earlier studies.

Beyond the head-to-head comparison, the study also explored innovative strategies to simplify or shorten treatment.

The study offers important insights into the therapeutic potential of short-chain fatty acids supplementation in MASLD, especially in non-obese patients.

This 12-month study explored the impact of ethanol-extracted curcumin on liver health, inflammation, and metabolic parameters in individuals with MASLD.

The biomarker identifies those at highest risk of non-adherence and helps determine how much support they receive during the intervention.

Despite the well-documented association between HBV and HCC, the exact mechanisms driving HBV-induced HCC remain largely unknown.

Biliary atresia is the most common surgical cause of cholestatic jaundice in infants and the leading reason for paediatric liver transplants

A recent prospective study explored the effectiveness of using indocyanine green to improve intraoperative detection of bile leakage.

Discover a study that found that individuals with higher baseline IL-1β levels experienced greater improvements in liver health following weight loss.

The results suggest that while MASLD is common in patients with T2DM in primary care, advanced liver disease is rare.

The findings highlight the potential for behavioural strategies, such as dietitian-led interventions, to play a key role in managing liver health.

Results showed that patients receiving the combination therapy experienced a median progression-free survival of 5.8 months, compared with 4.0 months.

This study explored the effects of various metabolic abnormalities, such as central obesity, high blood pressure, and elevated high-sensitivity C-reactive protein (hsCRP), on liver steatosis and fibrosis.

Discover more about strong evidence that public health measures, such as raising alcohol prices and restricting access can significantly reduce alcohol consumption.

Dapagliflozin shows promise for treating MASH, improving liver outcomes without worsening fibrosis in a major trial.

A 2023 global call to action by over 300 experts highlighted the need for clear, cross-specialty care pathways to support earlier identification and referral of people at risk.

In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.

These figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in paediatric populations.